ClinicalTrials.gg
CompletedNCT04150107Updated Jun 2, 2022Results posted

A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes

A Phase 2 interventional study of ORMD-0801 Treatment A and ORMD-0801 Treatment B in Type 1 Diabetes, sponsored by Oramed, Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus, Type 1 — 4 open to participants now, 4 under way, none of them phase 3. Insulin · Diabetes Mellitus, Type 1.

Enrollment
21st of 51
30 · median 20
Started
2019
with 3 others
Phase 2
16 of 51
none open now
Registered
44th of 51
by date

Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, this one is the 21st largest by enrollment, is one of 4 that started in 2019, is one of 16 in phase 2, and was the 44th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 51 studies testing insulin in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This study is a Phase 2 randomized, crossover study comparing ORMD-0801 given QD versus TID in subjects with T1D. Subjects with T1D will have a screening visit (Visit 1) during which they will be required to review and sign the informed consent form. Medical history and demographics will be collected. Vital signs will be measured, physical exam will be performed, and blood and urine samples will be collected for hematology/chemistry/urinalysis

Placebo capsules will be given QD at bedtime during placebo run-in period 10 days prior to randomization.

Read the detailed description

This study is a Phase 2 randomized, crossover study comparing ORMD-0801 given QD versus TID in subjects with T1D. Subjects with T1D will have a screening visit (Visit 1) during which they will be required to review and sign the informed consent form. Medical history and demographics will be collected. Vital signs will be measured, physical exam will be performed, and blood and urine samples will be collected for hematology/chemistry/urinalysis. Eligible subjects will be scheduled to return to the clinic in 1 week (Visit 2). Subjects fulfilling all inclusion/exclusion criteria will have a CGM placed, provided with a diary, dispensed Placebo capsules and asked to return to the clinic in 10 Days (Visit 3, Day 1) for randomization. At Visit 3, data from CGM will be downloaded and diaries will be collected. Blood samples will be collected in fasting for chemistry and HbA1c. Subjects will be randomized to receive either ORMD-0801 24 mg given once daily at bedtime, or ORMD-0801 8 mg given three times a day, 45-90 minutes before meals.

Subjects will be instructed to continue their normal diet, and to adjust their basal and bolus insulin in the normal fashion. Subjects will be instructed to return to the clinic 10 days before Visit 5 (Visit 4, Day 18). At Visit 4, compliance will be assessed, IMP and diary dispensed and the CGM will be placed. Subjects will be instructed to return to the clinic in 10 days for Visit 5 (Day 28). At Visit 5 a fasting blood sample for chemistry panel and HbA1C will be drawn and after the diary has been collected and the CGM monitor removed, they will be crossed over to the alternate treatment regimen. IMP will be dispensed, and the subject will be asked to return 10 days before Visit 7 for Visit 6 (Day 46). At Visit 6, compliance will be checked, IMP and diary will be dispensed and the CGM will be placed. Subjects will be instructed to return in 10 days for Visit 7 (Day 56). At Visit 7 the CGM will be removed, compliance checked, the diary will be collected, and a blood sample will be drawn for a chemistry panel and HbA1C. A physical examination will be performed, and the subject will exit the study. Subjects will be provided with diaries at Visits 2, 4 and 6, and will be asked to capture the amount of basal and bolus exogenous insulin administered each day and calculate their carbohydrate count for all meals and snacks over the 10-day CGM monitoring period. Diaries will be collected at Visits 3, 5 and 7.

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 and older.
  • (BMI) of 19-30 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening.
  • T1D subjects must have:

    1. A documented history of type 1 diabetes for at least 6 months
    2. Should be on an MDI regimen
    3. C peptide levels of ˂ 0.7 ng/mL
    4. ≥ 6.5% to ≤10%
  • Females of must have a negative serum pregnancy test result at Screening.
  • Females who are not of childbearing potential are defined as:

    1. (defined as at least 12 months with no menses in women ≥45 years of age) or
    2. has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening
  • Subjects who are of childbearing potential must:

    a. agree to remain abstinent from heterosexual activity† or agree to use (or have their partner use) acceptable to prevent pregnancy within the projected duration of the trial and for 14 days after the last dose of blinded product. Two methods of contraception will be used to avoid pregnancy. Acceptable combinations of methods include: i. Use of one of the following double-barrier methods: diaphragm with spermicide and a condom; cervical cap and a condom; or a contraceptive sponge and condom ii. Use of hormonal contraception (any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent [including oral, subcutaneous, intrauterine and intramuscular agents, and cutaneous patch]) with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; vasectomy; or IUD. iii. Use of an IUD with one of the following: condom; diaphragm with spermicide; contraceptive sponge; vasectomy; or hormonal contraception (see above).

iv. Vasectomy with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; IUD; or hormonal contraception (see above).

†Abstinence can be used as the sole method of contraception if it is in line with the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of type 2 diabetes;
  • Evidence of unawareness of hypoglycemia unawareness, a documented plasma glucose ≤50 mg/dL in the absence of symptoms of hypoglycemia at Screening.
  • FPG >300 mg/dL at Screening; a single repeat test is allowable.
  • Use of the following medications:

    1. Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.
    2. Administration of systemic long-acting within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) within 30 days prior to Screening. Intra-articular and/or topical corticosteroids are not considered systemic.
  • Laboratory abnormalities at Screening including:

    1. Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X the
    2. Elevated liver enzymes ( (ALT), alanine aminotransferase (AST), alkaline phosphatase) >2X the upper limit of normal.
    3. Very high triglyceride levels (>600 mg/dL); a single repeat test is allowable.
    4. Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration.
  • Subject has a Screening systolic blood pressure ≥165 mmHg or diastolic blood pressure ≥100 mmHg. Subjects will be allowed to take a BP rescue medication.
  • Any abnormality at Screening or cardiovascular disease. Clinically significant cardiovascular disease will include:

    a. History of stroke, , or myocardial infarction within 6 months prior to Screening,

  • History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening.
  • Presence of any clinically significant endocrine disease according to the Investigator (euthyroid subjects on replacement therapy will be included if the dosage of thyroxine is stable for at least six weeks prior to Screening).
  • Presence of any clinically significant condition (in the opinion of the Investigator) that might interfere with the evaluation of study medication, such as significant renal, hepatic, gastrointestinal (GI), cardiovascular (CV), immune disease, blood dyscrasias or any disorders causing hemolysis or unstable red blood cells, or clinically important hematological disorders (i.e. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) at Screening.
  • History of gastrointestinal disorders (e.g. hypochlorhydria) with the potential to interfere with drug absorption.
  • Presence or history of cancer within the past 5 years of Screening, with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer.

    1. A subject with a history of >5 years prior to Screening should have no evidence of residual or recurrent disease.
    2. A subject with a history of melanoma, leukemia, lymphoma, or renal carcinoma is excluded.
  • Positive history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic or C, primary biliary cirrhosis, or active symptomatic gallbladder disease.
  • Positive history of .
  • Known allergy to soy.
  • Subject is on a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide), within 8 weeks prior to Screening. Subjects who have had bariatric surgery are also excluded.
  • S ubject is pregnant or breast-feeding.
  • Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking) at Screening.
  • At the Principal Investigator's discretion, any condition or other factor that is deemed unsuitable for subject enrollment into the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Placebo then Treatment A then Treatment B

    Treatment administered in the following order: 1. Period 1: Placebo (Fish Oil Capsule) 2. Period 2: Treatment A: 24 mg ORMD-0801;(16 mg + 8 mg capsules) Once Daily (QD) at Bedtime 3. Period 3:Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals

    Drug: ORMD-0801 Treatment A · Drug: ORMD-0801 Treatment B · Other: Placebo

  • Experimental
    Placebo then Treatment B then Treatment A

    Treatment administered in the following order: 1. Period 1: Placebo (Fish Oil Capsule) 2. Period 2:Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals 3. Period 3: Treatment A: 24 mg ORMD-0801;(16 mg + 8 mg capsules) Once Daily (QD) at Bedtime Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals

    Drug: ORMD-0801 Treatment A · Drug: ORMD-0801 Treatment B · Other: Placebo

Interventions

  • Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime

    Also known as: Oral Insulin

  • Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals

    Also known as: Oral Insulin

  • OtherPlacebo

    Fish oil capsule

06

What researchers measure

Primary outcomes

  1. Average Exogenous Basal Insulin Compared to Baseline (Placebo)

    The least squares means difference of basal exogenous insulin between treatment A and placebo and treatment B and placebo, utilized over the final ten (10) days of each treatment period

    Time frame: Combined Final ten days of each treatment period. Period1 (days -8 to 1)Period 2 (days 19 to 28) ,and Period 3 (days 47 to 56)

  2. Average Exogenous Bolus Insulin Compared to Baseline (Placebo)

    The amount of exogenous bolus insulin utilized over the final ten (10) days of each treatment period measured in mg/dL

    Time frame: Combined Final ten days of treatment per treatment period (Days -8 to 1, Days 19 to 28, and Days 47 to 56)

  3. Average Exogenous Total Insulin Compared to Baseline

    The Least Squares Mean Difeerence ( (mg/dL) of total exogenous insulin (the sum of basal + bolus exogenous insulin) over the final ten (10) days of treatment.

    Time frame: Combined Final ten days of treatment , day -8 to 1 (Period 1) Days 19 to 28 (Period 2), Days 47 to 56 (Period 3)

Secondary outcomes

  1. Daytime Average Mean Glucose Compared to Baseline

    Least Squares Mean Difference from Baseline of Daytime Average Mean Glucose over the final ten (10) days of each treatment and each treatment period as measured by CGM.

    Time frame: Combined Study days -8 to 1 (Period 1) Days 19 to 28 (Period 2), and days 47 to 56 (Period 3)

  2. Daytime Glucose Coefficient of Variation Compared to Baseline

    Least Squares Mean Continuous Glucose Monitor (CGM) Glucose Coefficient of Variation measured over daytime hours, compared to Baseline

    Time frame: Study Days -8 to 1 (Period 1), Days 19-28 (Period 2), and Days 47-56 (Period 3)

  3. Daytime Low Blood Glucose Index (LBGI) Compared to Baseline

    Least Squares Mean Daytime Low Blood Glucose Index (LBGI) measured over the last ten (10) days of the treatment period, compared to Baseline LBGI is a clinical scale that indicates the probability for hypoglycemia. Blood Glucose Variability is an important measure because it provides additional clarification for HbA1c value. The risk of hypglycemic events and the LBGI scale is defined as follows: Minimal Risk ( LBGI \< 1.1) Low Risk ( 1.1 \< LBGI \< 2.5) Moderate Risk (2.5 \< LBGI \< 5), HIgh Risk ( LBGI \> 5)

    Time frame: Combined Study Days -8 to 1 (Period 1), Days 19-28 (Period 2), and Days 47-56 (Period 3)

07

Results

Posted Jun 2, 2022

Participant flow

Period 1- Placebo run-in (All Patients)
Participant flow — Period 1- Placebo run-in (All Patients)
MilestonePlacebo Followed by Treatment A Followed by Treatment BPlacebo Followed by Treatment B Followed by Treatment A
Started1416
Completed1416
Not completed00
Period 2- Either Treatment A or B
Participant flow — Period 2- Either Treatment A or B
MilestonePlacebo Followed by Treatment A Followed by Treatment BPlacebo Followed by Treatment B Followed by Treatment A
Started1416
Completed1416
Not completed00
Period 3 Crossover-Treatment B or A
Participant flow — Period 3 Crossover-Treatment B or A
MilestonePlacebo Followed by Treatment A Followed by Treatment BPlacebo Followed by Treatment B Followed by Treatment A
Started1416
Completed1215
Not completed21
Withdrew: Adverse event20
Withdrew: Patient non-compliance01

Outcome measures

PrimaryAverage Exogenous Basal Insulin Compared to Baseline (Placebo)

The least squares means difference of basal exogenous insulin between treatment A and placebo and treatment B and placebo, utilized over the final ten (10) days of each treatment period

Time frame:
Combined Final ten days of each treatment period. Period1 (days -8 to 1)Period 2 (days 19 to 28) ,and Period 3 (days 47 to 56)
Reported as:
Least squares mean · mg/dL
Average Exogenous Basal Insulin Compared to Baseline (Placebo)
mg/dLBaselineTreatment ATreatment B
Least Squares Mean Baseline, Treatment A, Treatment B27.28 ± 2.48925.84 ± 2.48627.32 ± 2.492
Least Squares Mean Difference Treatment A minus Baseline or Treatment B minus BaselineNA ± NA-1.43 ± 0.3810.04 ± 0.421
Statistical analysis
  • Baseline vs Treatment A vs Treatment B · ANCOVA · p = <0.9223
PrimaryAverage Exogenous Bolus Insulin Compared to Baseline (Placebo)

The amount of exogenous bolus insulin utilized over the final ten (10) days of each treatment period measured in mg/dL

Time frame:
Combined Final ten days of treatment per treatment period (Days -8 to 1, Days 19 to 28, and Days 47 to 56)
Reported as:
Least squares mean · mg/dL
Average Exogenous Bolus Insulin Compared to Baseline (Placebo)
mg/dLBaselineTreatment ATreatment B
Least Squares Means Baseline, Treatment A, Treatment B20.63 ± 2.03320.77 ± 2.04520.54 ± 2.049
Least Squares Means Difference Treatment A minus Baseline, Treatmen B minus BaselineNA ± NA0.14 ± 0.634-0.09 ± 0.645
Statistical analysis
  • Baseline vs Treatment A vs Treatment B · ANCOVA · p = <0.8871
PrimaryAverage Exogenous Total Insulin Compared to Baseline

The Least Squares Mean Difeerence ( (mg/dL) of total exogenous insulin (the sum of basal + bolus exogenous insulin) over the final ten (10) days of treatment.

Time frame:
Combined Final ten days of treatment , day -8 to 1 (Period 1) Days 19 to 28 (Period 2), Days 47 to 56 (Period 3)
Reported as:
Least squares mean · mg/dL
Average Exogenous Total Insulin Compared to Baseline
mg/dLBaselineTreatment ATreatment B
Least Squares Mean47.92 ± 3.39546.64 ± 3.39747.88 ± 3.406
Least Squares Mean Difference Treatment A minus Baseline and Treatment B minus BaselineNA ± NA-0.127 ± 0.758-0.04 ± 0.798
Statistical analysis
  • Baseline vs Treatment A vs Treatment B · ANCOVA · p = <0.9641
SecondaryDaytime Average Mean Glucose Compared to Baseline

Least Squares Mean Difference from Baseline of Daytime Average Mean Glucose over the final ten (10) days of each treatment and each treatment period as measured by CGM.

Time frame:
Combined Study days -8 to 1 (Period 1) Days 19 to 28 (Period 2), and days 47 to 56 (Period 3)
Reported as:
Least squares mean · mg/dL
Daytime Average Mean Glucose Compared to Baseline
mg/dLBaselineTreatment ATreatment B
Least Sqaures Mean Baseline, Treatment A, Treatment B168.72 ± 5.825174.84 ± 5.957169.75 ± 5.930
Least Squares Mean Difference between each treatment and placeboNA ± NA6.12 ± 3.9661.02 ± 3.889
Statistical analysis
  • Baseline vs Treatment A vs Treatment B · ANCOVA · p = <0.7922
SecondaryDaytime Glucose Coefficient of Variation Compared to Baseline

Least Squares Mean Continuous Glucose Monitor (CGM) Glucose Coefficient of Variation measured over daytime hours, compared to Baseline

Time frame:
Study Days -8 to 1 (Period 1), Days 19-28 (Period 2), and Days 47-56 (Period 3)
Reported as:
Least squares mean · percent (%)
Daytime Glucose Coefficient of Variation Compared to Baseline
percent (%)BaselineTreatment ATreatment B
Least Squares Mean45.287 ± 2.319146.550 ± 2.307344.996 ± 2.2847
Least Squares Mean Differece between each treatment and placebo.NA ± NA1.64 ± 1.949-0.291 ± 1.9064
Statistical analysis
  • Baseline vs Treatment A vs Treatment B · ANCOVA · p = <0.9898
SecondaryDaytime Low Blood Glucose Index (LBGI) Compared to Baseline

Least Squares Mean Daytime Low Blood Glucose Index (LBGI) measured over the last ten (10) days of the treatment period, compared to Baseline LBGI is a clinical scale that indicates the probability for hypoglycemia. Blood Glucose Variability is an important measure because it provides additional clarification for HbA1c value. The risk of hypglycemic events and the LBGI scale is defined as follows: Minimal Risk ( LBGI \< 1.1) Low Risk ( 1.1 \< LBGI \< 2.5) Moderate Risk (2.5 \< LBGI \< 5), HIgh Risk ( LBGI \> 5)

Time frame:
Combined Study Days -8 to 1 (Period 1), Days 19-28 (Period 2), and Days 47-56 (Period 3)
Reported as:
Least squares mean · units on a scale
Daytime Low Blood Glucose Index (LBGI) Compared to Baseline
units on a scaleBaselineTreatment ATreatment B
Least Squares Mean Daytime Low Blood Glucose Index (LBGI) for Baseline,1.65 ± 0.2841.53 ± 0.2821.65 ± 0.288
Least Squares Mean Difference between Treatment A and Placebo, Treatment B and Placebo.NA ± NA-0.12 ± 0.2940.00 ± 0.297
Statistical analysis
  • Baseline vs Treatment A vs Treatment B · ANCOVA · p = <0.5165

Adverse events

Collected over Sixty-six (66) days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/30 (0%)0/30 (0%)0/30 (0%)
Treatment A ORMD-08010/30 (0%)0/30 (0%)9/30 (30%)
Treatment B ORMD-08010/30 (0%)0/30 (0%)6/30 (20%)
Most frequent other events
Most frequent other events
EventPlaceboTreatment A ORMD-0801Treatment B ORMD-0801
HypoglycemiaMetabolism and nutrition disorders0/302/300/30
DiarrhoeaGastrointestinal disorders0/302/300/30
NasopharangitisInfections and infestations0/300/301/30
OTITIS EXTERNAInfections and infestations0/300/301/30
SinusitisImmune system disorders0/300/301/30
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/301/301/30
Urinary Tract InfectionInfections and infestations0/301/301/30
HypoglycemiaMetabolism and nutrition disorders0/301/300/30
HypoglycemiaMetabolism and nutrition disorders0/301/301/30
Abdominal discomfortGastrointestinal disorders0/301/300/30

Baseline characteristics

All patients are first administered a placebo, or is the standard of care.

Age, Continuous
Age, Continuous(years)Placebo Followed by Treatment A Followed by Treatment BPlacebo Followed by Treatment B Followed by Treatment ATotal
Mean43.79285714 ± 12.6779314242.88125 ± 16.0413161443.30667 ± 12.22325
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Followed by Treatment A Followed by Treatment BPlacebo Followed by Treatment B Followed by Treatment ATotal
Female7815
Male7815
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Followed by Treatment A Followed by Treatment BPlacebo Followed by Treatment B Followed by Treatment ATotal
Hispanic or Latino011
Not Hispanic or Latino131528
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Followed by Treatment A Followed by Treatment BPlacebo Followed by Treatment B Followed by Treatment ATotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American000
White141428
More than one race000
Unknown or Not Reported000
Pre-dose Hb1Ac(%)
Pre-dose Hb1Ac(%)(percent)Placebo Followed by Treatment A Followed by Treatment BPlacebo Followed by Treatment B Followed by Treatment ATotal
Mean7.735714286 ± 0.7344355697.6125 ± 0.8484299227.67 ± 0.786
08

Study locations

1 site
  • Orange County Research Center
    Tustin, California 92780, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Feb 2020, 3 months.

Results were first posted in Jun 2022, 2 years 3 months after primary completion.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 3 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2019
First posted
Nov 4, 2019
StartActual
Oct 17, 2019
Primary completionActual
Feb 6, 2020
CompletionActual
Mar 12, 2020
Results first posted
Jun 2, 2022
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04150107
Lead sponsor
Oramed, Ltd.
Collaborators
Integrium
Responsible party
Sponsor
First posted
Nov 4, 2019
Start date
Oct 17, 2019
Primary completion
Feb 6, 2020
Completion
Mar 12, 2020
Results posted
Jun 2, 2022
Last update
Jun 2, 2022

Study contacts

Miriam Kidron, PhD
study director · Oramed Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion